Cancer Studies

Cancer Cell Mechanisms

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Professor Dean Fennell

  • Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Dr Marina Kriajevska

  • Receptor tyrosine kinase AXL as a biomarker in diagnostic and treatment of bladder cancer

Dr John Le Quesne

  • Molecular biology of early lung malignancy
  • Cell biological interpretation of tumour morphology and cytology
  • Translational dysregulation as a predictive biomarker

Professor Catrin Pritchard

  • Mechanisms of RAS/RAF oncogene induced tumour development
  • RAF/MAPK signalling in normal and cancer cells
  • Ex vivo patient relevant drug testing platforms

Dr Eugene Tulchinsky

  • Molecular Mechanisms of Epithelial Mesenchymal Transition in Cancer

Professor Simon Wagner

  • Translation regulation and lymphoproliferative disease
  • T-cell lymphoma genetics and function

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy

Chemoprevention

Professor Karen Brown

  • Preclinical and early clinical development of novel cancer chemopreventive agents
  • Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy

Professor Don J. L. Jones

  • Translation of candidate biomarkers to clinical use.
  • Use of high resolution LC-MS in the discovery and verification of biomarkers.
  • Investigation of protein quantification using Ion mobility.

Dr Alessandro Rufini

  • Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol.
  • Investigating and exploiting metabolic vulnerabilities in carcinogenesis .
  • Using circulating cell-free DNA for early detection of cancer

Professor Anne Thomas

  • The design and delivery of early phase clinical studies including chemoprevention strategies
  • Improving information exchange in oncology consultations

Early Detection

Professor Jacqui Shaw

  • Analysis of circulating cancer biomarkers through liquid biopsy
  • Molecular approaches to aid early detection of cancer
  • Molecular mechanisms of resistance to targeted therapy

Dr John Le Quesne

  • Molecular biology of early lung malignancy
  • Cell biological interpretation of tumour morphology and cytology
  • Translational dysregulation as a predictive biomarker

Dr David Moore

  • Combined molecular and morphological characterisation of early lung adenocarcinoma.Histological grading characteristics of lung adenocarcinoma with prognostic relevance
  • Assessment of the use of next generation sequencing for use as a diagnostic tool in tumours of uncertain origin
  • Identification of biomarkers of genomic instability, clinical implications and relevance to tumour biology and behaviour

Dr Gerald Saldhana

  • Predicting melanoma treatment using circulating free DNA
  • Identification and translation of melanoma tissue biomarkers

Personalised Medicine

Professor G. Don Jones

  • Development methods and biomarkers for the accurate measurement of radiogenic, oxidative and drug-induced DNA damage in vitro and in vivo
  • Investigation of mechanisms and agents to increase DNA damage as a means of enhancing cancer cell treatment sensitivity
  • Preclinical and clinical development of novel anti-cancer genotoxic agents

Professor Bruno Morgan

  • Imaging applications to monitor drug therapy
  • Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT

Professor Martin Dyer

  • Molecular cytogenetics of lymphoid malignancies
  • Antibody therapy of lymphoid malignancies
  • Development and assessment of novel agents for therapy of B-cell malignancies

Professor Dean Fennell

  • Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers

Professor Anne Thomas

  • The design and delivery of early phase clinical studies including chemoprevention strategies
  • Improving information exchange in oncology consultations

Professor Simon Wagner

  • PD-L1, PD-1 and other markers of the stroma or malignant T-cells in T-cell lymphoma